E. Liu

发表

Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective antagonist.

Ping Chen, S. Spergel, S. Chong, 2003, Journal of medicinal chemistry.

The discovery of sulfonamide endothelin antagonists and the development of the orally active ETA antagonist 5-(dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulf onamide.

N. Murugesan, E. Liu, M. Webb, 1994, Journal of medicinal chemistry.

Biphenylsulfonamide endothelin antagonists: structure-activity relationships of a series of mono- and disubstituted analogues and pharmacology of the orally active endothelin antagonist 2'-amino-N- (3,4-dimethyl-5-isoxazolyl)-4'-(2-methylpropyl)[1, 1'-biphenyl]-2-sulfonamide (BMS-187308).

S. Spergel, N. Murugesan, Z. Gu, 1998, Journal of medicinal chemistry.

Biphenylsulfonamide endothelin receptor antagonists. 2. Discovery of 4'-oxazolyl biphenylsulfonamides as a new class of potent, highly selective ET(A) antagonists.

S. Spergel, J. Barrish, N. Murugesan, 2000, Journal of Medicinal Chemistry.

Identification of Reversible Small Molecule Inhibitors of Endothelial Lipase (EL) which Demonstrate HDL-C Increase In Vivo.

David S. Taylor, K. Behnia, E. Liu, 2020, Journal of medicinal chemistry.

Antithrombotic and hemostatic effects of a small molecule factor XIa inhibitor in rats.

E. Liu, M. Ogletree, W. Schumacher, 2007, European journal of pharmacology.

Aroylguanidine-based factor Xa inhibitors: the discovery of BMS-344577.

J. Yanchunas, K. Kish, H. Klei, 2009, Bioorganic & medicinal chemistry letters.

Exogenous effects and endogenous production of endothelin in cardiac myocytes: potential significance in heart failure.

E. Liu, M. Webb, F. Spinale, 1996, The American journal of physiology.

Expression of endothelin receptor subtypes in rabbit saphenous vein.

E. Liu, M. Webb, C. Chao, 1993, Molecular pharmacology.

DuP 753, the selective angiotensin II receptor blocker, is a competitive antagonist to human platelet thromboxane A2/prostaglandin H2 (TP) receptors.

E. Liu, M. Webb, D. Harris, 1992, Prostaglandins.

Molecular characterization of angiotensin II type II receptors in rat pheochromocytoma cells

E. Liu, M. Webb, S. Moreland, 1992, Peptides.

Biphenylsulfonamide endothelin receptor antagonists. Part 3: structure-activity relationship of 4'-heterocyclic biphenylsulfonamides.

S. Spergel, J. Barrish, N. Murugesan, 2002, Bioorganic & medicinal chemistry letters.

Structure-activity studies of endothelin leading to novel peptide ETA antagonists.

E. Liu, J. Hunt, D. Floyd, 1993, Bioorganic & medicinal chemistry.

Effects of a thromboxane synthetase inhibitor and a thromboxane antagonist on release and activity of thromboxane A2 and prostacyclin in vitro.

E. Liu, M. Ogletree, R. Greenberg, 1985, Prostaglandins.

Conformationally constrained ortho-anilino diaryl ureas: discovery of 1-(2-(1'-neopentylspiro[indoline-3,4'-piperidine]-1-yl)phenyl)-3-(4-(trifluoromethoxy)phenyl)urea, a potent, selective, and bioavailable P2Y1 antagonist.

Steven A. Spronk, P. Lam, D. Schnur, 2013, Journal of medicinal chemistry.

Structure-activity relationships of monocyclic endothelin analogs

E. Liu, S. Moreland, P. Stein, 1991 .

Control of peptide disulfide regioisomer formation by mixed cysteine-penicillamine bridges. Application to endothelin-1.

E. Liu, M. Webb, S. Moreland, 2009, International journal of peptide and protein research.

Cloning and expression of a human endothelin receptor: subtype A.

M. Runge, E. Liu, M. Webb, 1992, The American journal of the medical sciences.

Vascular A10 cell membranes contain an endothelin metabolizing neutral endopeptidase.

E. Liu, M. Webb, K. Dickinson, 1991, Biochemical and biophysical research communications.

Discovery of nonbenzamidine factor VIIa inhibitors using a biaryl acid scaffold.

D. Cheney, S. Sheriff, E. Liu, 2013, Bioorganic & medicinal chemistry letters.

Amino(methyl) pyrrolidines as novel scaffolds for factor Xa inhibitors.

P. Lam, J. Macor, E. Liu, 2007, Bioorganic & medicinal chemistry letters.

Cyanoguanidine-based lactam derivatives as a novel class of orally bioavailable factor Xa inhibitors.

S. Chong, J. Yanchunas, K. Kish, 2009, Bioorganic & medicinal chemistry letters.

Synthesis and evaluation of acylguanidine FXa inhibitors.

E. Liu, P. Stein, Yan Shi, 2008, Bioorganic & medicinal chemistry letters.

Ketene aminal-based lactam derivatives as a novel class of orally active FXa inhibitors.

E. Liu, P. Stein, A. Rendina, 2005, Bioorganic & medicinal chemistry letters.

Arylsulfonamidopiperidone derivatives as a novel class of factor Xa inhibitors.

Ying Wang, Doree Sitkoff, Jing Zhang, 2011, Bioorganic & medicinal chemistry letters.

Development and validation of a platelet calcium flux assay using a fluorescent imaging plate reader.

E. Liu, L. Abell, 2006, Analytical biochemistry.

Evidence for functional thromboxane A2-prostaglandin H2 receptors in human placenta.

E. Liu, B. Wílkes, A. Hollander, 1989, The American journal of physiology.

Characterization of [5,6-3H]SQ 29,548 as a high affinity radioligand, binding to thromboxane A2/prostaglandin H2-receptors in human platelets.

E. Liu, S. Hall, M. Ogletree, 1988, The Journal of pharmacology and experimental therapeutics.

Identification of substituted benzothiazole sulfones as potent and selective inhibitors of endothelial lipase.

David S. Taylor, Brandon L. Parkhurst, E. Liu, 2019, Bioorganic & medicinal chemistry letters.

Binding and function of a potent new thromboxane receptor antagonist, BMS 180,291, in human platelets.

E. Liu, M. Webb, R. Misra, 1993, The Journal of pharmacology and experimental therapeutics.

Dissecting the Activation of Thienopyridines by Cytochromes P450 Using a Pharmacodynamic Assay In Vitro

E. Liu, L. Abell, 2011, Journal of Pharmacology and Experimental Therapeutics.

Comparison of a novel ETA receptor antagonist and phosphoramidon in renal ischemia.

E. Liu, M. Webb, S. Durham, 1995, Pharmacology.

Aspartate mutation distinguishes ETA but not ETB receptor subtype‐selective ligand binding while abolishing phospholipase C activation in both receptors

E. Liu, M. Webb, S. Krystek, 1995, FEBS letters.

Cloning and expression of an endothelin receptor subtype B from human prostate that mediates contraction.

E. Liu, M. Webb, B. Treiger, 1995, Molecular pharmacology.

BMS-182874 is a selective, nonpeptide endothelin ETA receptor antagonist.

E. Liu, M. Webb, S. Moreland, 1995, The Journal of pharmacology and experimental therapeutics.

The receptor binding affinity of monocyclic [Ala3,Xaa11]endothelin-1 analogs correlates with inducible helix length.

E. Liu, S. Moreland, J. Hunt, 1995, Bioorganic & medicinal chemistry.

Discovery and structure-activity relationships of sulfonamide ETA-selective antagonists.

E. Liu, P. Stein, D. Floyd, 1995, Journal of medicinal chemistry.

Site-specific biotinylation. A novel approach and its application to endothelin-1 analogs and PTH-analog.

E. Liu, J. Hunt, D. Floyd, 2009, International journal of peptide and protein research.

Mutation of peptide binding site in transmembrane region of a G protein-coupled receptor accounts for endothelin receptor subtype selectivity.

J. Novotný, E. Liu, M. Webb, 1994, The Journal of biological chemistry.

Mutational analysis of the endothelin type A receptor (ETA): interactions and model of selective ETA antagonist BMS-182874 with putative ETA receptor binding cavity.

J. Barrish, E. Liu, M. Webb, 1996, Biochemistry.

The endothelin receptor antagonist, BQ-123, inhibits angiotensin II-induced contractions in rabbit aorta.

E. Liu, M. Webb, S. Moreland, 1992, Biochemical and biophysical research communications.

Role of endothelin receptor subtype B (ET-B) in myocardial ischemia.

E. Liu, M. Webb, G. Grover, 1994, Life sciences.

Evidence of an endothelin-1 autocrine loop in cardiac myocytes: Relation to contractile function with congestive heart failure

E. Liu, M. Webb, F. Spinale, 1996 .

Design, structure-activity relationships, X-ray crystal structure, and energetic contributions of a critical P1 pharmacophore: 3-chloroindole-7-yl-based factor Xa inhibitors.

Jing Zhang, Doree Sitkoff, Kevin Kish, 2008, Journal of medicinal chemistry.

Design and synthesis of nonpeptidal endothelin receptor antagonists based on the structure of a cyclic pentapeptide

M. Hermsmeier, N. Murugesan, Z. Gu, 1995 .